Roche

ROCHE NEWSROOM (43 press releases)

Advanced Filtering & Sorting Options:

Skanska sold the office building Laboratoriet 5 in Solna, Sweden to Atlasmuren Fastigheter AB

PRESS RELEASE -- 26, April 2018

STOCKHOLM, 26-Apr-2018 — /EuropaWire/ — Skanska has sold the office building Laboratoriet 5 in Solna, Sweden to Atlasmuren Fastigheter AB for about SEK 200 M. The transaction will be recorded by Skanska Commercial Development Nordic in the second quarter 2018. … Read the full press release

John C. Reed, M.D. Ph.D. to succeed Elias Zerhouni, M.D. as Head of Global Research and Development at Sanofi

PRESS RELEASE -- 25, April 2018

PARIS, 25-Apr-2018 — /EuropaWire/ — Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service with the company. He will be succeeded in the post … Read the full press release

Roche: US FDA granted Breakthrough Therapy Designation to Hemlibra® for people with haemophilia A without factor VIII inhibitors

PRESS RELEASE -- 19, April 2018

Designation based on phase III HAVEN 3 study demonstrating Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis First medicine to show superior efficacy compared to prior factor VIII prophylaxis in an intra-patient comparison BASEL, 19-Apr-2018 — /EuropaWire/ — Roche … Read the full press release

GSK: We are delighted to start the phase III study and evolve our research programme for belimumab in systemic lupus erythematosus (SLE)

PRESS RELEASE -- 22, March 2018

LONDON, 22-Mar-2018 — /EuropaWire/ — GSK today announced the start of a phase III study investigating Benlysta (belimumab) in combination with rituximab in adult patients with systemic lupus erythematosus (SLE). Belimumab and rituximab have different but potentially complementary mechanisms of action. … Read the full press release

Roche: Phase III IMpower131 study met its co-primary endpoint of progression-free survival of people with a type of advanced squamous lung cancer

PRESS RELEASE -- 20, March 2018

BASEL, 20-Mar-2018 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane [albumin-bound … Read the full press release